| Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. | |
| | |
MedLine Citation:
|
PMID: 20824239 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The multifactorial nature of the pathogenesis of T2DM provides an opportunity to combine treatments that act upon different mechanisms. In addition to improving insulin resistance and pancreatic β-cell dysfunction, the GLP-1 agonists and DPP-4 inhibitors improve the impaired incretin response, as well as increase insulin secretion and reduce glucagon secretion, both in a glucose-dependent manner. As a result of these multiple actions, the GLP-1 agonists and DPP-4 inhibitors lower both fasting and postprandial glucose levels. The effects of GLP-1 agonists tend to be greater, probably because they produce pharmacologic levels of GLP-1 compared to physiologic levels with the DPP-4 inhibitors. Another difference is that unlike the DPP-4 inhibitors, the GLP-1 agonists also slow gastric emptying and promote satiety. |
| | |
Authors:
|
R Keith Campbell; Michael E Cobble; Timothy S Reid; Mansur E Shomali |
Related Documents
:
|
20206729 - Incretin-based therapies: review of current clinical trial data. 11168389 - Expression of glucagon-like peptide-1 (glp-1) receptor and the effect of glp-1-(7-36) a... 11415859 - Increased glucose-dependent insulinotropic polypeptide (gip) secretion in acromegaly. 16188169 - Utilizing the glp-1 signaling system to treat diabetes: sorting through the pharmacolog... 18947259 - New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin th... 16610399 - New therapies for type 2 diabetes based on glucagon-like peptide 1. 11811859 - Magnesium: its proven and potential clinical significance. 184089 - Hormone secretion and glucose metabolism in islets of langerhans of the isolated perfus... 7852539 - Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (dhea), dh... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: The Journal of family practice Volume: 59 ISSN: 1533-7294 ISO Abbreviation: J Fam Pract Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-08 Completed Date: 2010-12-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7502590 Medline TA: J Fam Pract Country: United States |
Other Details:
|
Languages: eng Pagination: S5-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pharmacotherapy, Washington State University College of Pharmacy, Pullman, WA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adamantane
/
analogs & derivatives,
therapeutic use Aged Blood Glucose Diabetes Mellitus, Type 2 / drug therapy*, physiopathology* Dipeptides / therapeutic use Female Glucagon / metabolism, therapeutic use Glucagon-Like Peptide 1 / analogs & derivatives, therapeutic use Humans Hypoglycemic Agents / therapeutic use* Incretins / therapeutic use* Insulin-Secreting Cells / physiology Male Metformin / therapeutic use Middle Aged Peptides / therapeutic use Pyrazines / therapeutic use Severity of Illness Index Time Factors Triazoles / therapeutic use Venoms / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Dipeptides; 0/Hypoglycemic Agents; 0/Incretins; 0/Peptides; 0/Pyrazines; 0/Triazoles; 0/Venoms; 0/liraglutide; 0/saxagliptin; 0/sitagliptin; 141732-76-5/exenatide; 281-23-2/Adamantane; 657-24-9/Metformin; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Distinguishing among incretin-based therapies. Introduction.
Next Document: Photochemical behavior of (diphosphine)(?(2)-tolane)Pt(0) complexes. Part A: Experimental considerat...